The BioCentury Show Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers
17 snips
Mar 20, 2026 
Najat Khan, CEO and President of Recursion Pharmaceuticals and former Johnson & Johnson R&D leader, explains how AI must prove itself by delivering real medicines. She discusses where AI is already adding value across biology, chemistry and clinical work. Topics include agentic AI for lab workflows, out-of-domain prediction, virtual cells and precompetitive consortia to build stronger shared data foundations.
AI Snips
Chapters
Transcript
Episode notes
AI Will Be Judged By Medicines It Delivers
- AI's value is judged by whether it produces differentiated medicines, not by flashy models or parameter counts.
- Public companies now must translate platform investments into clinical proof points while keeping models at the bleeding edge.
Apply Platform Components Where They Unlock Value
- Use the platform selectively: apply biology, chemistry, or clinical tools where they unlock the most value for a given program.
- Recursion found an FAP clinical insight — an allosteric MEK1-2 inhibitor — from phenomics-driven target discovery.
Design Molecules To Minimize Synthesis Burden
- Predict more and synthesize less by combining generative AI, physics-based methods and synthetically aware models.
- Recursion synthesizes ~90% fewer compounds and reaches candidates in ~17 months versus ~42 months industry average.